vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $139.2M, roughly 1.7× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 5.0%, a 30.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 11.5%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $14.9M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 7.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ADMA vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $242.1M |
| Net Profit | $49.4M | $12.1M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 6.8% |
| Net Margin | 35.5% | 5.0% |
| Revenue YoY | 18.4% | 11.5% |
| Net Profit YoY | -55.9% | -16.2% |
| EPS (diluted) | $0.20 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $242.1M | ||
| Q3 25 | $134.2M | $258.5M | ||
| Q2 25 | $122.0M | $240.7M | ||
| Q1 25 | $114.8M | $219.6M | ||
| Q4 24 | $117.5M | $217.2M | ||
| Q3 24 | $119.8M | $241.7M | ||
| Q2 24 | $107.2M | $224.9M | ||
| Q1 24 | $81.9M | $211.2M |
| Q4 25 | $49.4M | $12.1M | ||
| Q3 25 | $36.4M | $24.3M | ||
| Q2 25 | $34.2M | $19.9M | ||
| Q1 25 | $26.9M | $15.3M | ||
| Q4 24 | $111.9M | $14.4M | ||
| Q3 24 | $35.9M | $21.6M | ||
| Q2 24 | $32.1M | $15.8M | ||
| Q1 24 | $17.8M | $21.2M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 6.8% | ||
| Q3 25 | 38.0% | 10.2% | ||
| Q2 25 | 35.1% | 9.2% | ||
| Q1 25 | 30.4% | 7.7% | ||
| Q4 24 | 32.6% | 7.9% | ||
| Q3 24 | 33.1% | 10.3% | ||
| Q2 24 | 36.6% | 8.4% | ||
| Q1 24 | 26.7% | 8.0% |
| Q4 25 | 35.5% | 5.0% | ||
| Q3 25 | 27.1% | 9.4% | ||
| Q2 25 | 28.1% | 8.3% | ||
| Q1 25 | 23.4% | 7.0% | ||
| Q4 24 | 95.2% | 6.6% | ||
| Q3 24 | 30.0% | 8.9% | ||
| Q2 24 | 29.9% | 7.0% | ||
| Q1 24 | 21.7% | 10.0% |
| Q4 25 | $0.20 | $0.12 | ||
| Q3 25 | $0.15 | $0.23 | ||
| Q2 25 | $0.14 | $0.19 | ||
| Q1 25 | $0.11 | $0.15 | ||
| Q4 24 | $0.45 | $0.13 | ||
| Q3 24 | $0.15 | $0.20 | ||
| Q2 24 | $0.13 | $0.15 | ||
| Q1 24 | $0.08 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $16.3M |
| Total DebtLower is stronger | $72.1M | $84.0M |
| Stockholders' EquityBook value | $477.3M | $542.6M |
| Total Assets | $624.2M | $707.1M |
| Debt / EquityLower = less leverage | 0.15× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $16.3M | ||
| Q3 25 | $61.4M | $29.6M | ||
| Q2 25 | $90.3M | $35.0M | ||
| Q1 25 | $71.6M | $22.6M | ||
| Q4 24 | $103.1M | $57.4M | ||
| Q3 24 | $86.7M | $48.8M | ||
| Q2 24 | $88.2M | $62.5M | ||
| Q1 24 | $45.3M | $65.4M |
| Q4 25 | $72.1M | $84.0M | ||
| Q3 25 | $72.4M | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | $72.3M | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $477.3M | $542.6M | ||
| Q3 25 | $431.2M | $552.8M | ||
| Q2 25 | $398.3M | $548.3M | ||
| Q1 25 | $373.4M | $530.6M | ||
| Q4 24 | $349.0M | $554.5M | ||
| Q3 24 | $231.9M | $540.1M | ||
| Q2 24 | $188.3M | $532.7M | ||
| Q1 24 | $153.7M | $515.5M |
| Q4 25 | $624.2M | $707.1M | ||
| Q3 25 | $568.7M | $732.6M | ||
| Q2 25 | $558.4M | $731.8M | ||
| Q1 25 | $510.6M | $708.7M | ||
| Q4 24 | $488.7M | $746.4M | ||
| Q3 24 | $390.6M | $734.0M | ||
| Q2 24 | $376.4M | $756.8M | ||
| Q1 24 | $350.9M | $763.6M |
| Q4 25 | 0.15× | 0.15× | ||
| Q3 25 | 0.17× | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | 0.21× | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $20.0M |
| Free Cash FlowOCF − Capex | $34.6M | $14.9M |
| FCF MarginFCF / Revenue | 24.8% | 6.2% |
| Capex IntensityCapex / Revenue | 0.8% | 2.1% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $20.0M | ||
| Q3 25 | $13.3M | $33.2M | ||
| Q2 25 | $21.1M | $20.3M | ||
| Q1 25 | $-19.7M | $10.1M | ||
| Q4 24 | $50.2M | $16.6M | ||
| Q3 24 | $25.0M | $28.6M | ||
| Q2 24 | $45.6M | $18.7M | ||
| Q1 24 | $-2.2M | $15.0M |
| Q4 25 | $34.6M | $14.9M | ||
| Q3 25 | $-1.1M | $27.6M | ||
| Q2 25 | $18.7M | $17.6M | ||
| Q1 25 | $-24.4M | $8.4M | ||
| Q4 24 | $47.5M | $13.2M | ||
| Q3 24 | $24.0M | $27.5M | ||
| Q2 24 | $43.6M | $17.6M | ||
| Q1 24 | $-4.6M | $13.7M |
| Q4 25 | 24.8% | 6.2% | ||
| Q3 25 | -0.8% | 10.7% | ||
| Q2 25 | 15.3% | 7.3% | ||
| Q1 25 | -21.2% | 3.8% | ||
| Q4 24 | 40.4% | 6.1% | ||
| Q3 24 | 20.0% | 11.4% | ||
| Q2 24 | 40.7% | 7.8% | ||
| Q1 24 | -5.6% | 6.5% |
| Q4 25 | 0.8% | 2.1% | ||
| Q3 25 | 10.7% | 2.2% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 0.8% | ||
| Q4 24 | 2.3% | 1.5% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.5% | ||
| Q1 24 | 2.9% | 0.6% |
| Q4 25 | 0.72× | 1.65× | ||
| Q3 25 | 0.36× | 1.36× | ||
| Q2 25 | 0.62× | 1.02× | ||
| Q1 25 | -0.73× | 0.66× | ||
| Q4 24 | 0.45× | 1.15× | ||
| Q3 24 | 0.70× | 1.33× | ||
| Q2 24 | 1.42× | 1.19× | ||
| Q1 24 | -0.12× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
